Brief: Bioarctic - Therapeutic Goods Administration Decides Not To Register Lecanemab In Australia
03/03/2025 08:15
March 3 (Reuters) - BioArctic AB BIOAb.ST: THERAPEUTIC GOODS ADMINISTRATION DECIDES NOT TO REGISTER LECANEMAB IN AUSTRALIA PARTNER EISAI IS EXPLORING OPTIONS TO ENSURE ACCESS TO LECANEMAB IN AUSTRALIA PARTNER EISAI IS CONSIDERING SEEKING REVIEW BY ADMINISTRATIVE REVIEW TRIBUNAL Source text: ID:nWkr4sFYpT Further company coverage: [BIOAb.ST] (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on BioArctic AB
See all newsBrief: BioArctic And Lilly Sign Research, Collaboration Agreement
Brief: Bioarctic AB Declares Dividend Of Sek 2 Per Share With 1 June 2026 Record Date
Brief: Bioarctic Partner Eisai Presents Leqembi Sales Simulation
Sweden's BioArctic Q1 revenue drops sharply despite higher Leqembi royalties
Brief: BioArctic Q1 Operating Profit SEK 210.8 Million